CClinicalTrials.gg
CompletedNCT01764802Updated May 30, 2018

Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer

A Phase 2 interventional study of behavioral, psychological or informational intervention and behavioral, psychological or informational intervention in Ovarian Sarcoma, Ovarian Stromal Cancer and Stage I Uterine Sarcoma, sponsored by Ohio State University Comprehensive Cancer Center. Completed at 1 site in United States. Open to female participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by Ohio State University Comprehensive Cancer Center · Phase 2, Interventional, and Supportive care

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
Female
01

Study summary

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

Read the detailed description

PRIMARY OBJECTIVES:

I. Efficacy for reducing the severity of sexual distress, difficulty, and dysfunction in a phase II randomized clinical trial (RCT).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding gynecologic or breast cancer treatments and sexuality, and provision of a survivorship care plan (SCP) created using OncoLink over 1 hour following baseline assessment and before 6 months.

ARM II (Psychological intervention): Patients participate in individual or group therapy over 1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.

After completion of study treatment, patients are followed up at 3, 6, and 9 months.

02

Conditions studied

  • Ovarian Sarcoma
  • Ovarian Stromal Cancer
  • Stage I Uterine Sarcoma
  • Stage I Vaginal Cancer
  • Stage I Vulvar Cancer
  • Stage IA Cervical Cancer
  • Stage IA Endometrial Carcinoma
  • Stage IA Fallopian Tube Cancer
  • Stage IA Ovarian Epithelial Cancer
  • Stage IA Ovarian Germ Cell Tumor
  • Stage IA Primary Peritoneal Cavity Cancer
  • Stage IB Cervical Cancer
  • Stage IB Endometrial Carcinoma
  • Stage IB Fallopian Tube Cancer
  • Stage IB Ovarian Epithelial Cancer
  • Stage IB Ovarian Germ Cell Tumor
  • Stage IB Primary Peritoneal Cavity Cancer
  • Stage IC Fallopian Tube Cancer
  • Stage IC Ovarian Epithelial Cancer
  • Stage IC Ovarian Germ Cell Tumor
  • Stage IC Primary Peritoneal Cavity Cancer
  • Stage II Endometrial Carcinoma
  • Stage II Gestational Trophoblastic Tumor
  • Stage II Uterine Sarcoma
  • Stage II Vaginal Cancer
  • Stage II Vulvar Cancer
  • Stage IIA Cervical Cancer
  • Stage IIA Fallopian Tube Cancer
  • Stage IIA Ovarian Epithelial Cancer
  • Stage IIA Ovarian Germ Cell Tumor
  • Stage IIA Primary Peritoneal Cavity Cancer
  • Stage IIB Cervical Cancer
  • Stage IIB Fallopian Tube Cancer
  • Stage IIB Ovarian Epithelial Cancer
  • Stage IIB Ovarian Germ Cell Tumor
  • Stage IIB Primary Peritoneal Cavity Cancer
  • Stage IIC Fallopian Tube Cancer
  • Stage IIC Ovarian Epithelial Cancer
  • Stage IIC Ovarian Germ Cell Tumor
  • Stage IIC Primary Peritoneal Cavity Cancer
  • Stage III Gestational Trophoblastic Tumor
  • Stage III Uterine Sarcoma
  • Stage III Vaginal Cancer
  • Stage III Vulvar Cancer
  • Stage IIIA Cervical Cancer
  • Stage IIIA Endometrial Carcinoma
  • Stage IIIA Fallopian Tube Cancer
  • Stage IIIA Ovarian Epithelial Cancer
  • Stage IIIA Ovarian Germ Cell Tumor
  • Stage IIIA Primary Peritoneal Cavity Cancer
  • Stage IIIB Cervical Cancer
  • Stage IIIB Endometrial Carcinoma
  • Stage IIIB Fallopian Tube Cancer
  • Stage IIIB Ovarian Epithelial Cancer
  • Stage IIIB Ovarian Germ Cell Tumor
  • Stage IIIB Primary Peritoneal Cavity Cancer
  • Stage IIIC Endometrial Carcinoma
  • Stage IIIC Fallopian Tube Cancer
  • Stage IIIC Ovarian Epithelial Cancer
  • Stage IIIC Ovarian Germ Cell Tumor
  • Stage IIIC Primary Peritoneal Cavity Cancer
  • Breast Cancer

Keywords

  • Psychosexual Intervention
  • Cancer
  • Gynecologic Cancer
  • Breast Cancer
03

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Stage I-III gynecologic (any site) or breast cancer
  • Able to speak/read English
  • Able to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Prior non-gynecologic/breast cancer diagnosis
  • Refusal of any cancer treatment(s)
  • Non-ambulatory
  • Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
  • Major mental illness (e.g, schizophrenia, major depressive disorder)
  • Current/recent (prior 12 months) pregnancy
  • Residence > 70 miles from research site
04

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Arm I (enhanced standard care)

    Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.

    Other: behavioral, psychological or informational intervention

  • Experimental
    Arm II (psychological intervention)

    Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.

    Other: behavioral, psychological or informational intervention

Interventions

  • Otherbehavioral, psychological or informational intervention

    Participate in enhanced standard care

  • Otherbehavioral, psychological or informational intervention

    Participate in psychological intervention

05

What researchers measure

Primary outcomes

  1. Sexual behavior/repertoire (kissing, intercourse, etc.) graded using the Sexual Experiences Scale (SES)

    Multilevel modeling will be used to model time effects compared to repeated-measures analysis of variance (ANOVA) because it allows not only fitting different patterns of average change (i.e., linear, quadratic), but also estimates individual variability in the rate of change. Both linear and quadratic change models will be tested and an optimal model will be determined. 95% confidence intervals will be obtained.

    Time frame: Up to 2 months

  2. Sexual responsiveness (desire, arousal, orgasm) using the Female Sexual Functioning Index (FSFI)

    Principal components analysis yields six subscales: desire, arousal, lubrication, orgasm, satisfaction, and pain. Items are rated using the Likert scales. 95% confidence intervals will be obtained.

    Time frame: Up to 4 weeks

  3. Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)

    95% confidence intervals will be obtained.

    Time frame: Up to 2 months

  4. Sexual distress graded using the female Sexual Distress Scale (FSDS)

    The Likert scale will be used. 95% confidence intervals will be obtained.

    Time frame: Up to 4 weeks

  5. Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version

    Time frame: Up to 9 months

Secondary outcomes

  1. Emotional distress graded using the Profile of Mood States (POMS)

    The Likert scale will be used. 95% confidence intervals will be obtained.

    Time frame: Up to 9 months

  2. Depressive symptoms graded using the Center for Epidemiologic Studies Depression Scale (CES-D)

    The Likert scale will be used. 95% confidence intervals will be obtained.

    Time frame: Up to 9 months

  3. Health-related quality of life graded according to the RAND Medical Outcomes Study, Short-form 12 (SF-12)

    The eight primary subscales are summarized into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).

    Time frame: Up to 9 months

  4. Cancer-related stress graded according to the Impact of Events Scale-Revised (IES-R)

    Time frame: Up to 9 months

  5. Body change stress graded according to the Impact of Treatment Scale (ITS)

    Time frame: Up to 9 months

06

Study locations

1 site
  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
    Columbus, Ohio 43210, United States
07

References and documents

Related links

08

Registry details

Key details

Study ID
NCT01764802
Lead sponsor
Ohio State University Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Kristen Carpenter (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Jan 10, 2013
Start date
Oct 2010
Primary completion
Jun 1, 2017
Completion
Jun 1, 2017
Last update
May 30, 2018

Study contacts

Kristen M. Carpenter, Ph.D
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion